Status:
COMPLETED
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients
Lead Sponsor:
Phramongkutklao College of Medicine and Hospital
Conditions:
Dengue
Dengue With Warning Signs
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study aims to determine the efficacy of montelukast in reducing the incidence of dengue warning signs in adult dengue patients.
Detailed Description
Dengue has been the growing public health problem in many tropical countries. Almost 4 billion people were estimated to be at risk, with estimated 400 million infections occurring annually. In Asia, a...
Eligibility Criteria
Inclusion
- at least 18 years old
- diagnosis of dengue
- positive NS1 antigen or polymerase chain reaction (PCR) test
Exclusion
- any warning sign of dengue
- concurrent diagnosis of other causes of fever, such as malaria or heat stroke
- pregnancy
- being unable to take medication by mouth
- critical illness needing intubation or admission to an intensive care unit
- being unable to communicate
- other indication of montelukast
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 17 2023
Estimated Enrollment :
358 Patients enrolled
Trial Details
Trial ID
NCT04673422
Start Date
January 15 2021
End Date
June 17 2023
Last Update
July 18 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hatyai Hospital
Hat Yai, Changwat Songkhla, Thailand
2
Phramongkutklao Hospital
Bangkok, Thailand, 10400
3
Ananda Mahidol Hospital
Lopburi, Thailand, 15000
4
Fort Suranari Hospital
Nakhon Ratchasima, Thailand, 30000